Zacks Investment Research
21 Oct 2026, 22:51 UTC · 55m ago
Moderna (MRNA) Rises Higher Than Market: Key Facts
Impact · against what's priced in
The article provides no new catalysts for Moderna, as the provided earnings forecasts and revenue declines are already reflected in the market's expectations. The recent price surge to $245.81 indicates the market has fully transitioned to the extreme bull case for the oncology platform, rendering these forecasted quarterly losses immaterial.
- MRNA+0.00
Already priced in
- The price assumes
The current respiratory vaccine franchise, which generated $1.94 billion in FY2025 revenue despite a 39.2% year-over-year decline.
The forecasted quarterly revenue of $888.78 million (down 12.52% YoY) and annual revenue of $2.1 billion simply confirm the continuing volatility and contraction of the respiratory franchise that the market has already factored in.
What MRNA's price assumes · Sep 11
Top 2 movers · tap to explore
